Nektar Therapeutics Q3 2025 Earnings Recap

NKTR Q3 2025 November 8, 2025

Get alerts when NKTR reports next quarter

Nektar Therapeutics reports robust advancements in clinical trials, particularly for rezpegaldesleukin (REZPEG), positioning itself for potential market leadership in atopic dermatitis and alopecia areata.

Earnings Per Share Beat

$-1.85 vs $-2.85 est.

+35.1% surprise

Revenue Beat

11790000 vs 10439380 est.

+12.9% surprise

Market Reaction

1-Day +2.23%

5-Day +2.78%

30-Day -11.82%

See NKTR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Successfully advanced REZPEG into the Phase III development stage, targeting moderate to severe atopic dermatitis.
Strong preliminary results from the RESOLVE-AD study, showcasing REZPEG's differentiation from existing treatments, particularly for patients with comorbid asthma.
Planned presentations of 52-week maintenance data in Q1 and top-line results from alopecia areata studies are expected to further bolster the therapeutic profile.
Nektar aims to capture a significant portion of the $1 billion alopecia areata market with REZPEG as a potential first biologic therapy.
Upcoming FDA end-of-Phase II meeting anticipated to discuss Phase III plans for REZPEG in atopic dermatitis.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NKTR on AllInvestView.

Next Q1 2026